Cencora, Inc. (COR) community

CORNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends September 30

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 14/3026% above fair value

$359.03+9.65 (+2.76%)

Close on Nov 13, 2026Market cap $68.51BP/E 26.7Yield 0.61%

Community

Notes and questions about Cencora from other investors

No posts about COR yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Cencora's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jun 16, 2009
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is COR.

Compare: COR vs CAH · COR vs MCK · COR vs CI · COR vs RDY · COR vs CVS

Revenue growth5.1% · median 7.5%

Gross margin4.0% · median 12.3%

Operating margin0.9% · median 2.5%

Net margin0.8% · median 1.6%

Company	Revenue	Growth
CVS	$420.61B	+6.7%
MCK	$418.79B	+8.2%
COR	$332.77B	+5.1%
CI	$286.32B	+6.8%
CAH	$257.75B	+10.0%
RDY	–	–

Company

Next earnings (est.): Feb 3, 2027, before open
Exchange: NYSE
Industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Fiscal year ends: September 30
Employees: 51,000
Held by institutions: 96.1%
Auditor: Ernst& YoungLLP
SEC CIK: 1140859

Advertisement
300 × 250

See a number that looks wrong?